Показано 0 из 0
Дата |
---|
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.16
|
5.00
|
4.4954
|
4.20
|
4.4954
|
4.20
|
|
|
9 626.46
|
79.00
|
4.10
|
5.00
|
4.05
|
4.05
|
4.27
|
4.11
|
|
|
43 008.30
|
107.00
|
4.00
|
5.00
|
4.40
|
4.02
|
4.40
|
4.05
|
|
|
118 885.81
|
108.00
|
4.00
|
5.00
|
4.29
|
4.11
|
4.41
|
4.115
|
|
|
55 677.24
|
117.00
|
4.22
|
5.00
|
4.40
|
4.27
|
4.4212
|
4.29
|
|
|
54 305.00
|
98.00
|
4.22
|
4.48
|
4.41
|
4.3316
|
4.57
|
4.365
|
|
|
15 011.46
|
75.00
|
4.22
|
4.70
|
4.50
|
4.36
|
4.59
|
4.40
|
|
|
45 083.52
|
86.00
|
4.22
|
4.75
|
4.15
|
4.15
|
4.49
|
4.425
|
|
|
52 836.81
|
88.00
|
4.14
|
4.70
|
4.32
|
4.13
|
4.32
|
4.19
|
|
|
60 915.96
|
102.00
|
4.03
|
4.75
|
4.26
|
4.05
|
4.26
|
4.14
|
|
|
61 615.66
|
105.00
|
Marker Therapeutics, Inc., formerly known as TapImmune, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.